Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations

Journal of Allergy and Clinical Immunology

Volumn 136, Issue 6, 2015, Pages 1476-1485

  Teach, Stephen J ^a   Gill, Michelle A ^b   Togias, Alkis ^c   Sorkness, Christine A ^d   Arbes, Samuel J ^e   Calatroni, Agustin ^e   Wildfire, Jeremy J ^e   Gergen, Peter J ^c   Cohen, Robyn T ^f   Pongracic, Jacqueline A ^g   Kercsmar, Carolyn M ^h   Khurana Hershey, Gurjit K ^h   Gruchalla, Rebecca S ^b   Liu, Andrew H ^i,l   Zoratti, Edward M ^j   Kattan, Meyer ^k   Grindle, Kristine A ^d   Gern, James E ^d   Busse, William W ^d   Szefler, Stanley J ^l  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e RHO INC   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CHILDREN'S MEMORIAL HOSPITAL   (United States)

^h CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁱ DEPARTMENT OF MEDICINE   (United States)

^j HENRY FORD HOSPITAL   (United States)

^k Columbia University ^*  (United States)

^l UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Asthma; asthma exacerbations; fall season; IFN ; inhaled corticosteroid; omalizumab; rhinovirus

Indexed keywords

ALPHA INTERFERON; FLUTICASONE PROPIONATE; OMALIZUMAB; PLACEBO; ANTIASTHMATIC AGENT; CORTICOSTEROID;

ADOLESCENT; ANAPHYLAXIS; ARTICLE; ASTHMA; AUTUMN; BLOOD TOXICITY; BREAST DISEASE; CHILD; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; EYE TOXICITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INFESTATION; INNER EAR DISEASE; LUNG TOXICITY; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OTOTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCTIVE TOXICITY; RHINOVIRUS; SCHOOL; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS DETECTION; CLINICAL TRIAL; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; MONONUCLEAR CELL; SEASON; VIROLOGY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; OMALIZUMAB; RHINOVIRUS; SEASONS;

EID: 84952639005     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.09.008     Document Type: Article

References (31)

1. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007 J Allergy Clin Immunol 120 suppl 2007 S94 S138
2. S.J. Szefler, H. Mitchell, C.A. Sorkness, P.J. Gergen, G.T. O'Connor, W.J. Morgan, and et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial Lancet 372 2008 1065 1072
3. W.W. Busse, W.J. Morgan, P.J. Gergen, H.E. Mitchell, J.E. Gern, A.H. Liu, and et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children N Engl J Med 364 2011 1005 1015
4. J.I. Ivanova, R. Bergman, H.G. Birnbaum, G.L. Colice, R.A. Silverman, and K. McLaurin Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma J Allergy Clin Immunol 129 2012 1229 1235
5. T.R. Bai, J.M. Vonk, D.S. Postma, and H.M. Boezen Severe exacerbations predict excess lung function decline in asthma Eur Respir J 30 2007 452 456
6. S.J. Teach, P.J. Gergen, S.J. Szefler, H.E. Mitchell, A. Calatroni, J. Wildfire, and et al. Seasonal risk factors for asthma exacerbations among inner-city children J Allergy Clin Immunol 135 2015 1465 1473.e5
7. N.W. Johnston, S.L. Johnston, J.M. Duncan, J.M. Greene, T. Kebadze, P.K. Keith, and et al. The September epidemic of asthma exacerbations in children: a search for etiology J Allergy Clin Immunol 115 2005 132 138
8. W.W. Busse, R.F. Lemanske Jr., and J.E. Gern Role of viral respiratory infections in asthma and asthma exacerbations Lancet 376 2010 826 834
9. S. Baraldo, M. Contoli, E. Bazzan, G. Turato, A. Padovani, B. Marku, and et al. Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma J Allergy Clin Immunol 130 2012 1307 1314
10. P.A. Wark, S.L. Johnston, F. Bucchieri, R. Powell, S. Puddicombe, V. Laza-Stanca, and et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus J Exp Med 201 2005 937 947
11. M.A. Gill, G. Bajwa, T.A. George, C.C. Dong, I.I. Dougherty, N. Jiang, and et al. Counterregulation between the FcεRI pathway and antiviral responses in human plasmacytoid dendritic cells J Immunol 184 2010 5999 6006
12. S.R. Durrani, D.J. Montville, A.S. Pratt, S. Sahu, M.K. DeVries, V. Rajamanickam, and et al. Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children J Allergy Clin Immunol 130 2012 489 495
13. C.A. Sorkness, J.J. Wildfire, A. Calatroni, H.E. Mitchell, W.W. Busse, G.T. O'Connor, and et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents J Allergy Clin Immunology Pract 1 2013 163 171
14. M. Masoli, M. Weatherall, S. Holt, and R. Beasley Systematic review of the dose-response relation of inhaled fluticasone propionate Arch Dis Child 89 2004 902 907
15. H.W. Kelly, and H.S. Nelson Potential adverse effects of the inhaled corticosteroids J Allergy Clin Immunol 112 2003 469 479
16. Y.A. Bochkov, K. Grindle, F. Vang, M.D. Evans, and J.E. Gern Improved molecular typing assay for rhinovirus species A, B, and C J Clin Microbiol 52 2014 2461 2471
17. A. Fuhlbrigge, D. Peden, A.J. Apter, H.A. Boushey, C.A. Camargo Jr., J. Gern, and et al. Asthma outcomes: exacerbations J Allergy Clin Immunol 129 suppl 2012 S34 S48
18. R. Wang, S.W. Lagakos, J.H. Ware, D.J. Hunter, and J.M. Drazen Statistics in medicine - reporting of subgroup analyses in clinical trials N Engl J Med 357 2007 2189 2194
19. K.B. Weiss, J.E. Gern, N.W. Johnston, M.R. Sears, C.A. Jones, G. Jia, and et al. The Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school year Ann Allergy Asthma Immunol 105 2010 174 181
20. J. Oborne, K. Mortimer, R.B. Hubbard, A.E. Tattersfield, and T.W. Harrison Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial Am J Respir Crit Care Med 180 2009 598 602
21. E.R. Sutherland, T.S. King, N. Icitovic, B.T. Ameredes, E. Bleecker, H.A. Boushey, and et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma J Allergy Clin Immunol 126 2010 747 753
22. R.C. Strunk, L.B. Bacharier, B.R. Phillips, S.J. Szefler, R.S. Zeiger, V.M. Chinchilli, and et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study J Allergy Clin Immunol 122 2008 1138 1144.e4
23. D.J. Jackson, A. Sykes, P. Mallia, and S.L. Johnston Asthma exacerbations: origin, effect, and prevention J Allergy Clin Immunol 128 2011 1165 1174
24. M. Soto-Quiros, L. Avila, T.A. Platts-Mills, J.F. Hunt, D.D. Erdman, H. Carper, and et al. High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus J Allergy Clin Immunol 129 2012 1499 1505.e5
25. C.S. Murray, G. Poletti, T. Kebadze, J. Morris, A. Woodcock, S.L. Johnston, and et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children Thorax 61 2006 376 382
26. R. Djukanovic, S.J. Wilson, M. Kraft, N.N. Jarjour, M. Steel, K.F. Chung, and et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma Am J Respir Crit Care Med 170 2004 583 593
27. N.A. Hanania, S. Wenzel, K. Rosen, H.J. Hsieh, S. Mosesova, D.F. Choy, and et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study Am J Respir Crit Care Med 187 2013 804 811
28. P. Haldar, C.E. Brightling, B. Hargadon, S. Gupta, W. Monteiro, A. Sousa, and et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
29. I.D. Pavord, S. Korn, P. Howarth, E.R. Bleecker, R. Buhl, O.N. Keene, and et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Lancet 380 2012 651 659
30. N.A. Hanania, O. Alpan, D.L. Hamilos, J.J. Condemi, I. Reyes-Rivera, J. Zhu, and et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial Ann Intern Med 154 2011 573 582
31. M. Humbert, L.P. Boulet, R.M. Niven, Z. Panahloo, M. Blogg, and G. Ayre Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis Allergy 64 2009 81 84